The GLOW1 study shows that tarcocimab opens the door to earlier treatment with only 2 doses a year – a transformative potential for millions of patients DR U.S. Prevalence ~9,700,000 1 ~9% are currently treated due to treatment burden with existing anti- VEGF therapies Microhemorrhages visible on the retina even if no visual symptoms are present yet Image from a patient in the Phase 3 GLOW1 study in diabetic retinopathy Baseline Image from same patient after treatment with tarcocimab Week 48 Tarcocimab has the potential to improve outcomes for millions of patients with only 2 doses a year* * after 3 initiating doses 1. Roche epidemiology data from 2025 34